SR One leads $55M round for nasal alternative to EpiPen; Sanofi pulls website over accuracy concerns
California-based biopharma company ARS Pharmaceuticals said today that they have closed on a Series D round of $55 million. The round …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
